Skip to main content
SpringerLink
Log in

A Review of Quality of Life in Chronic Renal Failure

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

The quality of life of patients with end-stage renal disease (ESRD) has become an area of intensive investigation because of the high costs of renal-replacement therapy (dialysis or renal transplantation) and the rising prevalence of renal failure.

Studies comparing quality of life of patients using different forms of renal-replacement therapy are flawed by deficiencies in study design, such as lack of randomisation. Nevertheless, in both retrospective and prospective studies, transplantation has been shown to offer the highest levels of functional ability, employment and subjective quality of life. After case-mix adjustment, there is little difference between peritoneal dialysis and haemodialysis in terms of quality-of-life (QOL) outcomes. Vocational rehabilitation is an important aim of therapy; for patients below retirement age, pre-dialysis education and counselling are important in maintaining employment.

The elderly comprise the fastest-growing group of dialysis recipients; multiple comorbidities add to functional impairment in these patients. Subjective quality of life remains surprisingly high in many elderly patients, despite poor objective quality of life.

The quality of life of patients with diabetes mellitus and ESRD is lower than that of nondiabetic patients with ESRD. For selected patients with insulin-dependent diabetes mellitus, combined renal and pancreatic transplantation offers the advantage of freedom from insulin injections. Unfortunately, available evidence suggests only small improvements in quality of life with combined transplantation versus kidney-only transplantation, probably because many patients have developed multiple diabetic complications by the time of transplantation.

Epoetin alfa (erythropoietin) has been shown to improve quality of life in a number of trials. The optimal target haematocrit is a subject of controversy, but on current evidence, a target of 34 to 37% is reasonable. The degree of improvement in quality of life must be balanced against the additional costs of achieving a higher haematocrit.

Further study is necessary to clarify the optimal target haematocrit for epoetin alfa therapy, as well as the possible effects of nutritional support, growth hormone in paediatric patients, and combined renal and pancreatic transplantation in improving quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Disney APS, editor. Nineteenth report of the Australia and New Zealand Combined Dialysis and Transplant Registry (ANZDATA): Adelaide. Adelaide: ANZDATA, 1996

    Google Scholar 

  2. European Dialysis and Transplant Association. Report on the management of renal failure in Europe 1991. Nephrol Dial Transplant 1992; 7 Suppl. 2

    Google Scholar 

  3. Kurtin P, Nissenson AR. Variation in end-stage renal disease patient outcomes: what we know, what should we know, and how do we find it out? J Am Soc Nephrol 1993; 3(11): 1738–47

    PubMed  CAS  Google Scholar 

  4. Levinsky NG, Mesler DE. Measuring, managing and improving the quality of end-stage renal disease care. Am J Kidney Dis 1994; 24(2): 235–46

    PubMed  CAS  Google Scholar 

  5. Iglehart K. Health policy report. The American health care system: the end-stage renal disease program. N Engl J Med 1993; 328(5): 366–71

    Article  PubMed  CAS  Google Scholar 

  6. Schrier RW, Burrows-Hudson S, Diamond L, et al. Measuring, managing and improving quality in the end-stage renal disease treatment setting: committee statement. Am J Kidney Dis 1994; 24(2): 383–8

    PubMed  CAS  Google Scholar 

  7. Kutner NG. Assessing end-stage renal disease patients’ functioning and well-being: measurement approaches and implications for clinical practice. Am J Kidney Dis 1994; 24(2): 321–33

    PubMed  CAS  Google Scholar 

  8. Gutman RA, Stead WW, Robinson RR. Physical activity and employment status of patients on maintenance dialysis. N Engl J Med 1981; 304(6): 309–13

    Article  PubMed  CAS  Google Scholar 

  9. Churchill DN, Torrance GW, Taylor DW, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987; 10(1): 14–20

    PubMed  CAS  Google Scholar 

  10. Hart LG, Evans RW. The functional status of ESRD patients as measured by the Sickness Impact Profile. J Chronic Dis 1987; 40 Suppl. 1: 117S–30S

    Article  PubMed  Google Scholar 

  11. Tell GS, Mittelmark MB, Hylander B, et al. Social support and health-related quality of life in black and white dialysis patients. ANNA J 1995; 22(3): 301–8

    PubMed  CAS  Google Scholar 

  12. Laupacis A, Muirhead N, Keown P, et al. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron 1992; 60: 302–6

    Article  PubMed  CAS  Google Scholar 

  13. Park H, Bang WR, Kim SJ, et al. Quality of life of ESRD patients: development of a tool and comparison between transplant and dialysis patients. Transplant Proc 1992; 24(4): 1435–7

    PubMed  CAS  Google Scholar 

  14. Parfrey PS, Vavasour H, Bullock M, et al. Development of a health questionnaire specific for end-stage renal disease. Nephron 1989; 52: 20–8

    Article  PubMed  CAS  Google Scholar 

  15. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 (3 Suppl.): 217S–32S

    Article  Google Scholar 

  16. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of Chemotherapeutic Agents. New York: Columbia University, 1949: 191–205

    Google Scholar 

  17. Disney APS, editor. Eighteenth report of the Australian and New Zealand Combined Dialysis and Transplant Registry (ANZDATA): Adelaide. Adelaide: ANZDATA, 1995

    Google Scholar 

  18. Disney APS, editor. Seventeenth report of the Australian and New Zealand Combined Dialysis and Transplant Registry (ANZDATA). Adelaide: ANZDATA, 1994

    Google Scholar 

  19. Kutner NG, Brogan D, Fielding B, et al. Older renal dialysis patients and quality of life. Dial Transplant 1991; 20(4): 171–5

    Google Scholar 

  20. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981; 34: 585–597

    Article  PubMed  CAS  Google Scholar 

  21. Campbell A, Converse PE, Rodgers WL. The quality of American life: perceptions, evaluations and satisfactions. New York: Russell Sage Foundation, 1976

    Google Scholar 

  22. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res 1972; 7: 118–33

    PubMed  CAS  Google Scholar 

  23. McEwen J. The Nottingham Health Profile: a measure of perceived health. In: Teeling-Smith G, editor. Measuring the Social Benefits of Medicine. London: The Office of Health Economics, 1983: 75–84

    Google Scholar 

  24. Bergener M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805

    Article  Google Scholar 

  25. Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

    Article  PubMed  Google Scholar 

  26. Hornberger JC, Redelmeier DA, Peterson J. Variability among methods to assess patients’ well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992; 45(5): 505–12

    Article  PubMed  CAS  Google Scholar 

  27. Deniston OL, Carpentier-Alting P, Kneisley J, et al. Assessment of quality of life in end-stage renal disease. Health Serv Res 1989; 24(4): 555–78

    PubMed  CAS  Google Scholar 

  28. Kimmel PL, Peterson RA, Weihs KL, et al. Aspects of quality of life in hemodialysis patients. J Am Soc Nephrol 1995; 6(5): 1418–26

    PubMed  CAS  Google Scholar 

  29. Sensky T. Measurement of the quality of life in end-stage renal failure [letter]. N Engl J Med 1988; 319: 1353

    PubMed  CAS  Google Scholar 

  30. Nissenson AR, Prichard SS, Cheng IKP, et al. Non-medical factors that impact on ESRD modality selection. Kidney Int 1993; 43 (40 Suppl.): 120S–7S

    Google Scholar 

  31. Rosser RM, Kind P. A scale of valuations of states of illness: is there a social consensus? Int J Epidemiol 1978; 7: 347–58

    Article  PubMed  CAS  Google Scholar 

  32. Evans RW, Manninen DL, Garrison LP, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312(9): 553–9

    Article  PubMed  CAS  Google Scholar 

  33. Bremer BA, McCauley CR, Wrona RW, et al. Quality of life in end-stage renal disease: a re-examination. Am J Kidney Dis 1989; 13(3): 200–9

    PubMed  CAS  Google Scholar 

  34. Morris PLP, Jones B. Transplantation versus dialysis: a study of quality of life. Transplant Proc 1988; 20(1): 23–6

    PubMed  CAS  Google Scholar 

  35. Johnson JP, Clark R, McCauley CR, et al. The quality of life of hemodialysis and transplant patients. Kidney Int 1982; 22: 286–91

    Article  PubMed  CAS  Google Scholar 

  36. Simmons RG, Abress L. Quality-of-life issues for end-stage renal disease patients. Am J Kidney Dis 1990; 15(3): 201–8

    PubMed  CAS  Google Scholar 

  37. McClellan WM, Anson C, Birkeli K, et al. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 1991; 44(1): 83–9

    Article  PubMed  CAS  Google Scholar 

  38. Julius M, Kneisley JD, Carpentier-Alting P, et al. A comparison of employment rates in patients treated with continuous ambulatory peritoneal dialysis vs. in-centre hemodialysis. Arch Intern Med 1989; 149: 839–43

    Article  PubMed  CAS  Google Scholar 

  39. Gokal R. Quality of life in patients undergoing renal replacement therapy. Kidney Int 1993; 43 (40 Suppl.): 23S–7S

    Google Scholar 

  40. Kutner NG, Brogan DR. Disability labelling vs. rehabilitation rhetoric for the chronically ill: a case study in policy contradictions. J Appl Behav Sci 1985; 21: 169–83

    Article  PubMed  CAS  Google Scholar 

  41. Ferrans CE, Powers MJ. The employment potential of hemodialysis patients. Nursing Res 1985; 34: 273–7

    Article  CAS  Google Scholar 

  42. Wolcott DL, Nissenson AR, Landsverk J. Quality of life in chronic dialysis patients. Factors unrelated to dialysis modality. Gen Hosp Psychiatry 1988; 10: 267–77

    Article  PubMed  CAS  Google Scholar 

  43. Ferrans CE, Powers MJ. Quality of life of hemodialysis patients. ANNA J 1993; 20(5): 575–82

    PubMed  CAS  Google Scholar 

  44. Rasgon S, Schwankovsky L, James-Rogers A, et al. An intervention for employment among blue-collar workers with end-stage renal disease. Am J Kidney Dis 1993; 22(3): 403–12

    PubMed  CAS  Google Scholar 

  45. Devins GM, Binik YM. Predialysis psychoeducational interventions: establishing collaborative relationships between health service providers and recipients. Semin Dial 1996; 9(1): 51–5

    Article  Google Scholar 

  46. Kutner NG, Cardenas DD. Assessment of rehabilitation outcomes among chronic dialysis patients. Am J Kidney Dis 1982; 2: 128–32

    CAS  Google Scholar 

  47. Russell JD, Beecroft ML, Ludwin D, et al. The quality of life in renal transplantation — a prospective study. Transplantation 1992; 54(4): 656–60

    Article  PubMed  CAS  Google Scholar 

  48. Gorlen T, Ekeberg O, Abdelnoor M, et al. Quality of life after kidney transplantation. A 10–22 years follow-up. Scand J Urol Nephrol 1993; 27: 89–92

    Article  PubMed  CAS  Google Scholar 

  49. Evans RW. Quality of life assessment and the treatment of end-stage renal disease. Transplant Rev 1990; 4(1): 28–51

    Article  Google Scholar 

  50. Kutner NG, Brogan D, Kutner MH. End-stage renal disease treatment modality and patients’ quality of life. Am J Nephrol 1986; 6: 396–402

    Article  PubMed  CAS  Google Scholar 

  51. Sayag R, Kaplan de Nour A, Shapira Z, et al. Comparison of psychosocial adjustment of male nondiabetic kidney transplant and hospital hemodialysis patients. Nephron 1990; 54(3): 214–8

    Article  PubMed  CAS  Google Scholar 

  52. Bilous RW, Mauer SM, Sutherland DER, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin dependent diabetes. N Engl J Med 1989; 321(2): 80–5

    Article  PubMed  CAS  Google Scholar 

  53. Ramsay RC, Goetz FC, Sutherland DER, et al. Progression of diabetic retinopathy after transplantation for insulin dependent diabetes mellitus. N Engl J Med 1988; 318(4): 208–14

    Article  PubMed  CAS  Google Scholar 

  54. Solders G, Wilczek H, Gunnarsson R, et al. Effects of combined pancreatic and renal transplantation on diabetic neuropathy: a two year follow up. Lancet 1987; 2: 1232–5

    Article  PubMed  CAS  Google Scholar 

  55. Kennedy WR, Navarro X, Goetz FC, et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322(15): 1031–7

    Article  PubMed  CAS  Google Scholar 

  56. Bandell F, Vigano C, Secchi A, et al. Effect of pancreas transplantation on diabetic retinopathy: a 20-case report. Diabetologia 1991; 34 Suppl. 1: S92–4

    Article  Google Scholar 

  57. Chui A, Bovington KJ, Moylan D, et al. Progressive macroangiopathy in diabetics despite successful pancreas transplantation [abstract]. Twelfth Scientific Meeting, Transplant Society of Australia and New Zealand; 1994 Apr 20–22; Canberra: 15

  58. Nankivell BJ, Al-Harbi IS, Morris J, et al. Recovery of diabetic neuropathy after pancreas transplantation. Transplant Proc 1997; 29: 658–9

    Article  PubMed  CAS  Google Scholar 

  59. Kiebert GM, van Oosterhout ECAA, van Bronswijk H, et al. Quality of life after combined kidney-pancreas or kidney transplantation in diabetic patients with end-stage renal disease. Clin Transplant 1994; 8: 239–45

    PubMed  CAS  Google Scholar 

  60. Nathan DM, Fogel H, Norman D, et al. Long-term metabolic and quality of life results with pancreatic/renal transplantation in insulin-dependent diabetes mellitus. Transplantation 1991; 52(1): 85–91

    Article  PubMed  CAS  Google Scholar 

  61. Douzdjian V, Abecassis MM, Corry RJ, et al. Simultaneous pancreas-kidney versus kidney-alone transplants in diabetics: increased risk of early cardiac death and acute rejection following pancreas transplants. Clin Transplant 1994; 8: 246–51

    PubMed  CAS  Google Scholar 

  62. Stratta RJ, Taylor RJ, Ozaki CF, et al. The analysis of benefit and risk of combined pancreatic and renal transplantation versus renal transplantation alone. Surg Gynecol Obstet 1993; 177; 163–71

    PubMed  CAS  Google Scholar 

  63. Nakache R, Tyden G, Groth CG. Long-term quality of life in diabetic patients after combined pancreas-kidney transplantation or kidney transplantation. Transplant Proc 1994; 26(2): 510–1

    PubMed  CAS  Google Scholar 

  64. Bentdal OH, Fauchald P, Brekke IB, et al. Rehabilitation and quality of life in diabetic patients after successful pancreas-kidney transplantation. Diabetologia 1991; 34 Suppl. 1: 158S–9S

    Article  Google Scholar 

  65. Esmatjes E, Ricart MJ, Fernandez-Cruz L, et al. Quality of life after successful pancreas-kidney transplantation. Clin Transplant 1994; 8: 75–8

    PubMed  CAS  Google Scholar 

  66. Nakache R, Tyden G, Groth CG. Quality of life in diabetic patients after combined pancreas-kidney or kidney transplantation. Diabetes 1989; 38 Suppl. 1: 40S–2S

    Google Scholar 

  67. Piehlmeier W, Bullinger M, Nusser J, et al. Quality of life in type 1 (insulin-dependent) diabetic patients prior to and after pancreas/kidney transplantation in relation to organ function. Diabetologia 1991; 34 Suppl. 1: 150S–7S

    Article  Google Scholar 

  68. Zehr PS, Milde FK, Hart LK, et al. Impact of pancreas transplantation on quality of life of diabetic renal transplant recipients. Transplant Proc 1994; 26(2): 520–1

    PubMed  CAS  Google Scholar 

  69. Secchi A, Di Carlo V, Martinenghi S, et al. Effect of pancreas transplantation on life expectancy, kidney function and quality of life in uraemic type 1 (insulin dependent) diabetic patients. Diabetologia 1991; 34 Suppl. 1: 141S–4S

    Article  Google Scholar 

  70. Milde FK, Hart LK, Zehr PS. Pancreatic transplantation. Diabetes Care 1995; 18(1): 93–5

    Article  PubMed  CAS  Google Scholar 

  71. Voruganti LNP, Sells RA. Quality of life of diabetic patients after combined pancreatic-renal transplantation. Clin Transplant 1989; 3: 78–82

    Google Scholar 

  72. Hathaway DK, Hartwig MS, Milstead J, et al. Improvement in quality of life reported by diabetic recipients of kidney-only and pancreas-kidney allografts. Transplant Proc 1994; 26(2): 512–4

    PubMed  CAS  Google Scholar 

  73. Zehrer CL, Gross CR. Comparison of quality of life between pancreas/kidney and kidney transplant recipients: 1-year follow-up. Transplant Proc 1994; 26(2): 508–9

    PubMed  CAS  Google Scholar 

  74. Piehlmeier W, Bullinger M, Kirchberger I, et al. Prospective study of the quality of life in type 1 diabetic patients before and after organ transplantation. Transplant Proc 1994; 26(2): 522–3

    PubMed  CAS  Google Scholar 

  75. Calkins ME. Ethical issues in the elderly ESRD patient. ANNA J 1993; 20(5): 569–71

    PubMed  CAS  Google Scholar 

  76. Ifudo O, Mayers J, Matthew J, et al. Dismal rehabilitation in geriatric inner-city hemodialysis patients. JAMA 1994; 271(1): 29–33

    Article  Google Scholar 

  77. Chertow GM, Owen WF, Lazarus JM, et al. Outcomes of older patients receiving chronic dialysis [letter]. JAMA 1994; 272(4): 274

    Article  PubMed  CAS  Google Scholar 

  78. McKevitt PM, Jones JF, Marion RR. The elderly on dialysis: physical and psychosocial functioning. Dial Transplant 1986; 15(3): 130–7

    Google Scholar 

  79. Barrett BJ, Vavasour HM, Major A, et al. Clinical and psychological correlates of somatic symptoms in patients on dialysis. Nephron 1990; 55(1): 10–5

    Article  PubMed  CAS  Google Scholar 

  80. Roscoe JM, Smith LF, Williams EA, et al. Medical and social outcome in adolescents with end-stage renal failure. Kidney Int 1991; 40: 948–53

    Article  PubMed  CAS  Google Scholar 

  81. Watkins SL. Use of recombinant human growth hormone in children undergoing dialysis. Semin Dial 1994; 7(6): 421–8

    Article  Google Scholar 

  82. Foreman JW, Chan JCM. Chronic renal failure in infants and children. J Pediatr 1988; 113(5): 793–800

    Article  PubMed  CAS  Google Scholar 

  83. Fine RN. Choosing a dialysis therapy for children with end stage renal disease. Am J Kidney Dis 1984; 4(3): 249–52

    PubMed  CAS  Google Scholar 

  84. Reynolds JM, Garralda ME, Jameson RA, et al. How parents and families cope with chronic renal failure. Arch Dis Child 1988; 63: 821–6

    Article  PubMed  CAS  Google Scholar 

  85. Churchill DN, Bird DR, Taylor DW, et al. Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients. Am J Nephrol 1992; 12: 412–8

    Article  PubMed  CAS  Google Scholar 

  86. Moreno F, Lopez JM, Sanz-Guajardo D, et al. Evaluation of quality of life in dialysis patients: results of the Spanish national study on quality of life in dialysis [abstract]. Thirteenth International Congress of Nephrology; 1995 July 2–6; Madrid: 561

  87. Harris LE, Luft FC, Rudy DW, et al. Clinical correlates of functional status in patients with chronic renal insufficiency. Am J Kidney Dis 1993; 21(2): 161–6

    PubMed  CAS  Google Scholar 

  88. Evans EW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263(6): 825–30

    Article  PubMed  CAS  Google Scholar 

  89. Levin NW, Lazarus M, Nissenson AR. National cooperative rHu erythropoietin study in patients with chronic renal failure: an interim report. Am J Kidney Dis 1993; 22 Suppl. 1: 3–12

    PubMed  CAS  Google Scholar 

  90. Beusterien KW, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7(5): 763–73

    PubMed  CAS  Google Scholar 

  91. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anaemic hemodialysis patients. Am J Kidney Dis 1989; 14(2): 14–8

    PubMed  CAS  Google Scholar 

  92. Moreno F, Valderrabano F, Aracil FJ, et al. Influence of haematocrit on quality of life of haemodialysis patients [abstract]. Nephrol Dial Transplant 1994: 9(7): 1034

    Google Scholar 

  93. Harris DCH, Chapman JR, Stewart JH, et al. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 1991; 21: 693–700

    Article  PubMed  CAS  Google Scholar 

  94. Lundin AP, Akerman MJH, Chesler RM, et al. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron 1991; 58: 315–9

    Article  PubMed  CAS  Google Scholar 

  95. Robertson HT, Haley NR, Guthrie M, et al. Recombinant erythropoietin improves exercise capacity in anaemic haemodialysis patients. Am J Kidney Dis 1990; 15(4): 325–32

    PubMed  CAS  Google Scholar 

  96. Canadian Erythropoietin Study Group. Association between recombinant erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300: 573–8

    Article  Google Scholar 

  97. Wizeman V, Schafer R, Kramer W. Follow up of cardiac changes induced by anaemia compensation in normotensive hemodialysis patients with left ventricular hypertrophy. Nephron 1993; 64: 202–6

    Article  Google Scholar 

  98. Macdougal IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489–93

    Article  Google Scholar 

  99. Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis 1992; 20 (1 Suppl. 1): 21–4

    PubMed  CAS  Google Scholar 

  100. Marsh JT, Brown WS, Wolcott D, et al. rHuEPO treatment improves brain and cognitive function of anaemic dialysis patients. Kidney Int 1991; 39: 155–63

    Article  PubMed  CAS  Google Scholar 

  101. Schaeffer RM, Kokot F, Wernze H, et al. Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role for prolactin. Clin Nephrol 1989; 31(1): 1–5

    Google Scholar 

  102. Lundin AP. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy. Semin Nephrol 1989; 9 (1 Suppl.): 22–9

    PubMed  CAS  Google Scholar 

  103. McMahon LP, Johns JA, McKenzie A, et al. Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 1992; 7: 1199–206

    PubMed  CAS  Google Scholar 

  104. Cannella G, La Canna G, Sandrini M, et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991; 6: 31–7

    PubMed  CAS  Google Scholar 

  105. Eschbach LW, Aquiling T, Haley NR, et al. The long term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992; 38 Suppl. 1: 98–103

    Google Scholar 

  106. Mann JFE. Hypertension and cardiovascular effects: long-term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 1995; 10 Suppl. 2: 80–4

    PubMed  Google Scholar 

  107. Harris DCH. Erythropoietin. In: Disney APS, editor. Fifteenth report of Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Adelaide: ANZDATA, 1992: 128–34

    Google Scholar 

  108. McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of haemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992; 12: 162–9

    Article  PubMed  CAS  Google Scholar 

  109. Eschbach JW, Glenny R, Robertson T, et al. Normalizing the haematocrit in hemodialysis patients with EPO improves quality of life and is safe [abstract]. J Am Soc Nephrol 1993; 4: 425

    Google Scholar 

  110. Walls J. Haemoglobin: is more better? Erythropoiesis 1995; 6: 16–20

    Google Scholar 

  111. Lim VS, Fangman J, Flanigan MJ, et al. Effect of recombinant erythropoietin on renal function in humans. Kidney Int 1990; 37: 131–6

    Article  PubMed  CAS  Google Scholar 

  112. US Recombinant Human Erythropoietin Predialysis Study Group. Double blind, placebo controlled study of the therapeutic use of recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991; 18(1): 50–9

    Google Scholar 

  113. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25(4): 548–54

    Article  PubMed  CAS  Google Scholar 

  114. Roth D, Smith RD, Schulman G, et al. Effects of r-HuEPO on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777–84

    PubMed  CAS  Google Scholar 

  115. Austrian Multicentre Study Group of r-HuEPO in predialysis patients. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 1992; 61: 399–403

    Article  Google Scholar 

  116. Eschbach JW. The future of r-HuEPO. Nephrol Dial Transplant 1995; 10 Suppl. 2: 96–109

    PubMed  Google Scholar 

  117. Schedule of Pharmaceutical Benefits. Canberra: Commonwealth Department of Health and Family Services, May 1996

  118. Stevens ME, Summerfield GP, Hall AA, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. BMJ 1992; 304: 474–7

    Article  PubMed  CAS  Google Scholar 

  119. Sheingold S, Chuchill D, Muirhead N, et al. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Soc Sci Med 1992; 34(9): 983–91

    Article  PubMed  CAS  Google Scholar 

  120. Macdougal IC. Poor response to erythropoietin. BMJ 1995; 310: 1424–5

    Article  Google Scholar 

  121. Harris DCH. Low-dosage epoetin in maintenance haemodialysis: costs and quality of life improvements. Pharmacoeconomics 1994; 5(1): 18–28

    Article  PubMed  CAS  Google Scholar 

  122. Muirhead N, Churchill DN, Goldstein M, et al. Comparison of subcutaneous and intravenous recombinant erythropoietin for anaemia in hemodialysis patients with significant co-morbid disease. Am J Nephrol 1992; 12: 303–10

    Article  PubMed  CAS  Google Scholar 

  123. Eidmak I, Friedborg MO, Ladefoged SD, et al. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant 1991; 7: 526–9

    Google Scholar 

  124. Taylor JE, Belch JJF, Fleming LW, et al. Erythropoietin response and route of administration. Clin Nephrol 1994; 41: 297–302

    PubMed  CAS  Google Scholar 

  125. Sunder-Plassmann G, Horl WH. Optimizing low dose r-Hu-EPO combined with low dose I.V. iron therapy in hemodialysis patients [abstract]. J Am Soc Nephrol 1994; 5: 478

    Google Scholar 

  126. Barclay PG, Fischer ER, Harris DCH. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin. Clin Nephrol 1993; 40: 277–80

    PubMed  CAS  Google Scholar 

  127. Macdougal IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 1994; 3: 620–5

    Article  Google Scholar 

  128. Macdougal IC, Tucker B, Thompson J, et al. A randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. J Am Soc Nephrol 1993; 4: 428

    Google Scholar 

  129. Leese B, Hutton J, Maynard A. The costs and benefits of the use of erythropoietin in the treatment of anaemia arising from chronic renal failure: a European study. York: Centre for Health Economics Occasional Paper, 1990

    Google Scholar 

  130. McNamee P, van Doorslaer, Segaar R. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Int J Technol Assess Health Care 1993; 9(4): 490–504

    Article  PubMed  CAS  Google Scholar 

  131. Nicholls AJ. Enhanced quality of life in dialysis patients treated with erythropoietin: are the benefits worth the cost? Erythropoiesis 1992; 3: 46–9

    Google Scholar 

  132. Bergstrom J. Why are dialysis patients malnourished? Am J Kidney Dis 1995; 26(1): 229–41

    Article  PubMed  CAS  Google Scholar 

  133. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994; 24(6): 1002–9

    PubMed  CAS  Google Scholar 

  134. Lazarus JM. Nutrition in hemodialysis patients. Am J Kidney Dis 1993; 21(1): 99–105

    PubMed  CAS  Google Scholar 

  135. Smolle KH, Kaufmann P, Holzer H, et al. Intradialytic parenteral nutrition in malnourished patients on chronic haemodialysis therapy. Nephrol Dial Transplant 1995; 10(8): 1411–6

    PubMed  CAS  Google Scholar 

  136. Ikizler TA, Wingard RL, Hakim RM. Malnutrition in peritoneal dialysis patients: etiological factors and treatment options. Perit Dial Int 1995; 15 (5 Suppl.): S63–6

    PubMed  CAS  Google Scholar 

  137. Schulman G, Wingard RL, Hutchison RL, et al. The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Kidney Dis 1993; 21(5): 527–34

    PubMed  CAS  Google Scholar 

  138. Blake PG. Growth hormone and malnutrition in dialysis patients. Perit Dial Int 1995; 15(6): 210–6

    PubMed  CAS  Google Scholar 

  139. Digenis GE, Dombros NV, Oreopoulos DG. Recent developments in peritoneal dialysis. Curr Opin Nephrol Hypertens 1992; 1(2): 203–9

    Article  PubMed  CAS  Google Scholar 

  140. Kopple JD, Bernerd D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47(4): 1148–57

    Article  PubMed  CAS  Google Scholar 

  141. Siskind MS, Lien Y-HH. Effect of intradialytic parenteral nutrition on quality of life in hemodialysis patients. Int J Artif Organs 1993; 16(8): 599–603

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Renal Medicine, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia

    Darren S. Parsons &  David C. H. Harris

Authors
  1. Darren S. Parsons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David C. H. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parsons, D.S., Harris, D.C.H. A Review of Quality of Life in Chronic Renal Failure. Pharmacoeconomics 12, 140–160 (1997). https://doi.org/10.2165/00019053-199712020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199712020-00005

Keywords

Search

Navigation